Peloton Interactive Inc vs Sanofi SA — how do they compare? Peloton Interactive Inc trades at $6.25 (market cap $2.75B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is far larger — about 38.1× Peloton Interactive Inc's market cap, and Sanofi SA pays a 5.53% dividend while Peloton Interactive Inc pays none. Which is the better fit depends on your goals.
| PTON | SNY | |
|---|---|---|
Market Cap | $2.75B | $104.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $9.00 | $52.34 |
52-Week Low | $3.71 | $41.33 |
Enterprise Value | $3.35B | $121.38B |
Dividend Yield | — | 5.53% |
Signals from Pluang's Aura AI — not financial advice
Peloton (PTON) trades at $6.36, up 3.92% on the day, showing improved technical momentum with bullish moving average signals. The company demonstrates significant operational turnaround with positive operating cash flow of $333M in 2025 and projected net profitability in 2026. Recent earnings show mixed results with Q3 2025 beating expectations but subsequent quarters missing. The stock faces challenges from declining revenue trends and negative shareholder equity of -$519.2M, though cost-cutting measures and new leadership appointments provide potential catalysts.
The outlook remains cautiously optimistic with analyst consensus pointing to 18% upside to the $7.50 price target. Key opportunities include continued cash flow improvement and potential market share stabilization, while risks center on persistent revenue declines and high debt levels. The company's inclusion in the S&P SmallCap 600 index provides additional institutional visibility, though execution on growth initiatives remains critical for sustained recovery.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Trailing returns across standard periods
Latest headlines on both assets
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →